Loading...
Market
Story
Eli Lilly's Zepbound Achieves 47% Greater Weight Loss Than Novo Nordisk's Wegovy in Phase 3B Trial
Dec 4, 2024, 11:52 AM
Eli Lilly & Co. has reported that its weight-loss drug Zepbound, also known as tirzepatide, outperformed Novo Nordisk A/S's Wegovy, or semaglutide, in a Phase 3B head-to-head clinical trial. The trial showed that Zepbound led to an average weight loss of 20.2% over 72 weeks, compared to 13.7% for Wegovy. Participants using Zepbound lost 50.3 lbs (22.8 kg), while those on Wegovy lost 33.1 lbs (15.0 kg). This 47% greater relative weight reduction has been highlighted by Eli Lilly as a significant achievement in the treatment of obesity. The results have led to a rise in Eli Lilly's stock price, reflecting investor confidence in the drug's potential.
View original story
Similar markets
European Medicines Agency (EMA) • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
Therapeutic Goods Administration (TGA) • 25%
Other • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
Approved in US only • 33%
Approved in US and one other major market • 33%
Approved in US and multiple other major markets • 33%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Less than 20 • 25%
20 to 40 • 25%
40 to 60 • 25%
More than 60 • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of the World • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%